A New Blood Test Could Predict This Diabetes Symptom Before It Starts

Reported by MindBodyGreen.

For the more than 500 million people living with diabetes worldwide, vision loss ranks among the most devastating complications — and for years, the cruel reality has been that by the time diabetic eye disease shows up on a scan, the damage is already done. A study published in PLOS Medicine suggests that window of helplessness may finally be closing.

The condition at the center of this research is diabetic retinal neurodegeneration (DRN) — the progressive breakdown of the retina that can lead to severe visual impairment and eventual blindness. But DRN isn't contained to your eyes. Scientists consider it a kind of neurological signal flare: it's been linked to cognitive decline, dementia, and peripheral nerve damage in the hands and feet. What's deteriorating at the back of your eye may be mirroring what's happening across your entire nervous system. The problem, until now, has been that DRN is only caught after symptoms surface — at which point intervention is largely futile.

What the AI-Assisted Blood Test Actually Does

To get ahead of that damage, researchers developed a machine-learning model called Pro-DRN that can predict DRN risk before a single symptom appears — using nothing more than a blood draw. According to MindBodyGreen, the team analyzed plasma samples from 1,492 patients with type 2 diabetes enrolled in the Guangzhou Diabetic Eye Study, tracked 1,218 of them via retinal scans over six years, and validated results against a separate 502-person cohort from the UK BioBank. They isolated 71 plasma proteins tied to inflammation and cellular maintenance — biological disruptions that appear to signal early retinal nerve damage long before it becomes visible. Fed into the predictive model, those proteins allowed Pro-DRN to outperform the best existing risk tool by 26%. The researchers have already made it available online for clinical use.

Some important caveats: the model is built on associations between protein levels and DRN, not confirmed causal links. It won't overhaul diabetes care tomorrow. But the implications of a proactive screening tool — one that could redirect monitoring and early intervention toward the patients most likely to need it — are hard to understate. Right now, the standard of care is almost entirely reactive. Pro-DRN points toward something better: risk-stratified care that catches neurological deterioration while there's still time to act, whether through lifestyle adjustments, neuroprotective treatment, or simply closer specialist follow-up.

If you're managing diabetes, this is worth bringing to your next appointment — because the most powerful thing a blood test can do is tell you something before your body has to.

Read the original at MindBodyGreen.